WeDoctor and China Resources Pharmaceutical Commerce Launch 'Internet Medicine Consortium' to Drive Digital Transformation of the Medical Industry through 'Three-Medical Linkage'

The outbreak of the COVID-19 pandemic has brought new challenges to various industries. How the pharmaceutical industry can leverage digitalization to break through bottlenecks and seize new opportunities for industrial upgrading has become a focal point of attention. During the fight against the epidemic, digital-driven innovative measures in healthcare services have demonstrated robust vitality and have emerged as a new engine driving innovation and development in the pharmaceutical industry in the post-pandemic era.

On November 30, the “Signing and Launch Ceremony of the Internet Medicine Consortium” was held at WeDoctor’s headquarters in Hangzhou. WeDoctor Group and China Resources Pharmaceutical Commercial Group Co., Ltd. signed a strategic cooperation agreement to jointly initiate the industry-wide “Internet Medicine Consortium.” This initiative brings together upstream and downstream pharmaceutical enterprises, hospitals, physicians, and other healthcare stakeholders to collaboratively build a pharmaceutical supply chain and an internet medical technology cooperation platform. By doing so, it aims to achieve digital-driven integration of medical care, pharmaceuticals, and health insurance services, promote the digital upgrading of the pharmaceutical distribution supply chain, and provide patients with efficient, inclusive, and high-quality pharmaceutical and healthcare services.

Chairman andCEOLiao Jieyuan,Mu Hong, General Manager of China Resources Pharmaceutical Commercial Group Co., Ltd.Leaders from both companies attended the event and witnessed the signing ceremony. Wang, Chief Financial Officer of WeDoctorYongcaiwith Zhao, Assistant General Manager and Chief Financial Officer of China Resources Pharmaceutical Commercial Group Co., Ltd.WeiRepresentatives from both parties signed the agreement, with business heads from all regions across China in attendance at the signing and launch ceremony.

Both parties stated that the “Internet Pharmaceutical Consortium” will address pain points in the pharmaceutical distribution industry by leveraging internet hospitals as a platform and disease categories as the main thread. It will connect upstream with pharmaceutical manufacturers and distributors, and reach downstream to physicians and patients through internet hospitals, chronic disease management centers, and the pharmaceutical consortium itself. Across multiple service scenarios—both within and outside hospitals, as well as online and offline—it will establish rapid channels connecting patients with high-quality pharmaceutical and medical services. According to the plan, the “Internet Pharmaceutical Consortium” will operate on a disease-specific basis, fostering an open, professional, and shared full-industry ecosystem through innovations in pharmaceutical service models and health insurance service models, thereby reducing costs and improving efficiency in the pharmaceutical distribution sector.

Since the beginning of this year, the Chinese government has continuously rolled out policies to support the development of the “Internet + Healthcare” industry. Internet-based medical services have also been included in the national health insurance reimbursement system. Meanwhile, the pandemic has accelerated the formation of new habits among both patients and physicians. The “Internet Pharmaceutical Consortium,” jointly launched by the two parties, will establish an integrated internet pharmaceutical service system featuring three closed loops: pharmaceutical, medical, and operational. This initiative aims to precisely match and connect high-quality resources across the upstream and downstream segments of the industrial chain. Furthermore, under a diversified payment framework encompassing out-of-pocket expenses, basic medical insurance, and commercial health insurance, it will provide patients with high-quality, convenient, efficient, and safe pharmaceutical and healthcare services.

“The journey of pharmaceuticals from manufacturers to patients is fraught with pain points such as protracted processes, low efficiency, and information asymmetry,” said Liao Jieyuan in his address. He stated that the collaboration integrates the respective strengths of the digital health platform and the pharmaceutical distribution enterprise, continuously optimizing the drug distribution process through digital technologies to create value for multiple stakeholders across the supply and demand chain.

“The collaboration between WeDoctor and China Resources Pharmaceutical Commercial Group aligns with the trend of digital upgrading in the industry and represents the manifestation of the ‘three-medical linkage’ across the value chain of the healthcare sector,” said Mu Hong in his address. He stated that WeDoctor serves as an integrator of channels and capabilities within the healthcare industry, and the capabilities and resources accumulated by China Resources Pharmaceutical Commercial Group on the distribution side will inject new momentum into the digital transformation of the pharmaceutical distribution sector through their partnership.

At the signing ceremony, the first implemented project of the partnership—the “Run Xiaoyi” Hemophilia Patient Care Center—was officially launched. By accessing the dedicated zone via the “Rare Diseases” section in the WeDoctor app, users can conveniently obtain online services such as consultation and appointment registration, expert-led health education, and guidance for purchasing medications from professional pharmacies.

It is understood that WeDoctor, as an internationally leading digital health platform, has built a digital closed-loop service ecosystem encompassing “medical care, pharmaceuticals, and health insurance,” providing users with digital healthcare services for diagnosis, disease management, and overall health maintenance. WeDoctor Internet General Hospital has currently launched 30 internet hospitals across China, 18 of which are designated as medical insurance providers. The platform connects more than 7,600 large and medium-sized hospitals, 22 chronic disease management centers, 26,000 primary healthcare institutions, and 33,000 pharmacies. Over 250,000 physicians practice online on the platform, which has more than 210 million real-name registered users.

China Resources Pharmaceutical Commercial Group Co., Ltd. is a leading pharmaceutical distribution enterprise in the industry, boasting a high-quality, efficient modern supply chain and logistics warehousing system. Its marketing network covers all 31 provinces and municipalities across China, providing pharmaceutical product logistics and distribution, marketing promotion, and other innovative value-added services to nearly 10,000 upstream suppliers and over 90,000 downstream customers.